GlassScriptPhysician profile
Jay Joseph Kaner
NPI 1316995384
$27,815.43
in general payments reported to CMS, 2019-2025
69 companies · $3,105 in 2025
The $3,105 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,141 · 2020: $3,175 · 2021: $5,758 · 2022: $3,828 · 2023: $4,342 · 2024: $3,467 · 2025: $3,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,870.71 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,569.07 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $2,302.64 | 2019-2025 | |
| Abbvie INC. | $2,063.82 | 2019-2025 | |
| Ucb, INC. | $1,997.17 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,524.79 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $1,399.88 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Amgen INC. | $1,062.78 | 2019-2025 | Aimovig, Uplizna |
| Validus Pharmaceuticals LLC | $955.75 | 2019-2023 | Equetro |
| Lilly USA, LLC | $933.71 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Pfizer INC. | $828.99 | 2019-2025 | |
| Neurelis, INC. | $701.62 | 2020-2025 | Valtoco |
| Genzyme Corporation | $670.26 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $637.27 | 2019-2025 | Ingrezza, Ongentys |
| Harmony Biosciences LLC | $557.77 | 2020-2025 | Wakix |
| Amneal Pharmaceuticals LLC | $548.60 | 2019-2025 | Rytary, Crexont, Ongentys |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kaner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.